SCHEMBL10014902

SCHEMBL10014902

Cc1c(C(O)c2ccc3cccnc3c2)ncn1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
OGA O60502 4/20 0.43
MEN1 O00255 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
NR4A2 P43354 1/20 0.38
TRPM8 Q7Z2W7 2/20 0.36
MET P08581 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644193 0.80 CYP3A4 (0.39) ALDH1A1OGAMEN1CASP1CASP7
SCHEMBL30644683 0.76 UGT2B7 (0.56) ALDH1A1OGAMEN1CASP1CASP7
SCHEMBL17541507 0.76 UGT2B7 (0.56) ALDH1A1OGAMEN1CASP1CASP7
SCHEMBL7097024 0.73 ALDH1A1 (0.51) ALDH1A1OGAMEN1CASP1CASP7
SCHEMBL401341 0.73 NR4A2 (0.49) ALDH1A1OGAMEN1CASP1CASP7
SCHEMBL10014901 0.69 ALDH1A1 (0.44) ALDH1A1MEN1CASP1CASP7KMT2A
SCHEMBL642083 0.69 CYP3A4 (0.40) ALDH1A1OGAMEN1CASP1CASP7
SCHEMBL903412 0.69 ALDH1A1 (0.58) ALDH1A1OGAMEN1CASP1CASP7
SCHEMBL24312390 0.69 ALDH1A1 (0.50) ALDH1A1OGAMEN1CASP1CASP7
SCHEMBL6853770 0.69 ALDH1A1 (0.50) ALDH1A1OGAMEN1CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119807-B2 Quinolynylmethylimidizoles as therapeutic agents ALLERGAN, INC. (US) 2012-02-21 US disclosed
US-20100076020-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2010-03-25 US disclosed
US-20090286829-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076020-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS TUBB3, TUBB1, NQO2 ALDH1A1 899/4885OGA 4090/4885MEN1 1547/4885
US-20090286829-A1 QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ADRA2C, ADRA2B, ADRB3 ALDH1A1 1423/4885OGA 3879/4885MEN1 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.